One more intriguing characteristic of Hic-5 is that its tissue distribution is rather limited (normally expressed in the lung, spleen, and smooth muscle layer of tissues) as compared with paxillin (which is ubiquitously expressed), thus it may serve as a more specific and safer target for HCC therapy. The gene discussed is TGFB1I1; the disease is hepatocellular carcinoma.